KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Other Non Operating Income (2019 - 2023)

Aquestive Therapeutics (AQST) has 3 years of Other Non Operating Income data on record, last reported at -$1.0 million in Q4 2023.

  • For Q4 2023, Other Non Operating Income changed N/A year-over-year to -$1.0 million; the TTM value through Sep 2024 reached -$1.0 million, down 191.5%, while the annual FY2023 figure was -$1.4 million, N/A changed from the prior year.
  • Other Non Operating Income reached -$1.0 million in Q4 2023 per AQST's latest filing, down from -$353000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $13.8 million in Q4 2021 and bottomed at -$4.9 million in Q3 2019.
  • Average Other Non Operating Income over 3 years is $1.9 million, with a median of -$691000.0 recorded in 2023.